PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia; I.M. Sechenov First Moscow State Medical University, MOH, Moscow, Russia; Kashirskoye roadway, 34А, 1115522, Moscow, Russia; Trubetskaya str, 8, bdg. 2, 2119991, Moscow, Russia. Electronic address: nasonov@irramn.ru.\', \'RPharm JSC, Leninsky prospect 111, 11942, Moscow, Russia. Electronic address: mikesamsonov@yahoo.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0753-3322(20)30891-X10.1016/j.biopha.2020.110698
?:hasPublicationType
?:journal
  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
is ?:pmid of
?:pmid
?:pmid
  • 32920514
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32920514>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32920514>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all